Authors

Tasneem Al-Najjar

Publications 4

Research article Open access

Successful Treatment of Recalcitrant Actinomycetoma of Gluteal Area with Combined Medical Treatment and Surgical Excision with Graft Reconstruction

Lutfi Al-Kathiri, Tasneem Al-Najjar, Abla Al-Asmaili · Oman Medical Journal · 2020 · 10.5001/omj.2020.29

Mycetoma, formerly known as Madura foot, is a chronic, localized, gradually increasing in size, granulomatous exogenous infection of the skin and subcutaneous tissue with risks of bone and visceral involvement. It is unevenly found worldwide but it is endemic in tropical and subtropical countries. Two groups of mycetom …

Research article Open access

Sea Urchin Granuloma of the Hands: A Case Report

Lutfi Al-Kathiri, Tasneem Al-Najjar, Ibrahim Sulaiman · Oman Medical Journal · 2019 · 10.5001/omj.2019.68

Penetrating wounds from sea urchin spines are marine injuries that may cause morbidity in humans. Seasonal fishing for abalone in Dhofar is associated with an increase in the number of these injuries, as divers may strike their extremities, especially the dorsum of hands and fingers, on the rocks where Echinoderms and …

Research article Open access

Severe Nodulocystic Acne not Responding to Isotretinoin Therapy Successfully Treated with Oral Dapsone

Lutfi Al-Kathiri, Tasneem Al-Najjar · Oman Medical Journal · 2018 · 10.5001/omj.2018.79

Nodulocystic acne is a severe form of acne which can result in significant damage to the skin with great impact on quality of life. Oral isotretinoin considered to be the best treatment for such cases. Although it has a high rate of success and its efficacy is well established in the treatment of nodulocystic acne, it …

Research article Open access

A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid

Lutfi Al-Kathiri, Varghese Mercyamma, Tasneem Al-Najjar · Oman Medical Journal · 2018 · 10.5001/omj.2018.65

Toxic epidermal necrolysis (TEN), a severe form of Stevens-Johnson syndrome, is an acute life-threatening adverse drug reaction with a mortality rate of approximately 30%. Primary treatment of TEN is usually supportive. The use of intravenous immunoglobulin (IVIG) and corticosteroids are still uncertain, as there are o …

Co-authors